-
Arena Pharma (ARNA) APD334 Data Positive But Well Behind S1P1 Competitors - BMO Capital
-
BMO Capital Keeps Arena Pharma (ARNA) at 'Market Perform' Following BELVIQ Combo Update
-
Arena Pharma (ARNA) Posts Modest BELVIQ Sales, BMO Capital Notes
-
Arena Pharma (ARNA) BELVIQ TRx up 5.3%
-
Streetinsider.com's Hot Lunchtime Reads 11/27: (AVAV) (TSLA) (OREX) (VJET)
-
Notable Analyst Rating Changes 06/25: (NFLX) (NVDA) (SNDK) Upgraded; (ARNA) (RIMM) (AN) Downgraded
-
Arena (ARNA) Snubs Downgrade, Now Higher on the Session
-
Another Bear Roars at Arena (ARNA); Says Numbers, Potential Overblown
-
Arena (ARNA) volatility elevated into PDUFA and downgrade
-
BMO Capital Downgrades Arena Pharma (ARNA) to Market Perform Ahead of PDUFA
-
With Arena Pharmaceuticals (ARNA) Halted Ahead of AdCom, There Will Be Other Ways to Play...
-
Notable 52-Week Highs and Lows of the Day 05/09: (ARNA) (DIS) (DF) High; (PCS) (CQB) (STEC) Low
-
Notable Analyst Rating Changes 05/09: (STJ) (ARNA) (UA) Upgraded; (AET) (MRVL) (HLF) Downgraded
-
BMO Capital Upgrades Arena Pharma (ARNA) to Outperform, Raises Target 600%
-
BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform
-
Notable Analyst Rating Changes 12/23: CRR, ARNA, SAAS Upgraded; ERIC, HOV, LOGI, NDAQ Downgraded
-
Morning Movers 09/17: CRXL, STU, PSTI, AEZS, CBLI, VITA, EDMC Higher; ARNA, TTHI, OREX, HOOK Lower
-
Notable Analyst Rating Changes 09/15: NETL, PWE, RDC, EQR Upgraded; ARNA, MU, NOK, TYC Downgraded
-
Jefferies, BMO Issue Afternoon Downgrades on Arena Pharma (ARNA)